How Time to Onset of Symptom Relief in OASIS 1 and 2 May Affect Patient Satisfaction

Rapid symptom improvement is a key determinant of patient confidence in therapy. In this segment, Genevieve Neal-Perry, MD, PhD, reports that participants treated with elinzanetant (Lynkuet) experienced meaningful reductions in VMS within approximately 1 week—earlier than what is typically expected with many hormonal and nonhormonal therapies. This early onset allows clinicians to counsel patients that treatment response can be assessed quickly.

Neal-Perry emphasizes that timely relief can be transformative for patients who have lived with chronic, disruptive symptoms. Early improvement supports a sense of control and validation, often translating into high patient satisfaction. From a clinical perspective, these experiences reinforce the value of therapies that demonstrate both rapid and sustained benefit.

The segment also addresses treatment adherence. Neal-Perry notes that patients are more likely to discontinue medications that require prolonged periods before benefit is perceived. In contrast, the fast onset associated with elinzanetant may encourage continued use, thereby increasing the likelihood of sustained symptom control and long-term quality-of-life improvement.